Dr. Reddy's Laboratories Limited (RDY)
USD 14.55
(0.48%)
USD 14.55
(0.48%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 95.87 Billion INR | -18.48% |
| 2023 | 117.61 Billion INR | 53.14% |
| 2022 | 76.8 Billion INR | 9.53% |
| 2021 | 70.11 Billion INR | 14.48% |
| 2020 | 61.24 Billion INR | -2.07% |
| 2019 | 62.54 Billion INR | -2.87% |
| 2018 | 64.38 Billion INR | -0.73% |
| 2017 | 64.85 Billion INR | 3.5% |
| 2016 | 62.66 Billion INR | 6.0% |
| 2015 | 59.11 Billion INR | 18.78% |
| 2014 | 49.76 Billion INR | 28.34% |
| 2013 | 38.77 Billion INR | 14.01% |
| 2012 | 34.01 Billion INR | 23.08% |
| 2011 | 27.63 Billion INR | 7.41% |
| 2010 | 25.72 Billion INR | 1.65% |
| 2009 | 25.31 Billion INR | 14.79% |
| 2008 | 22.05 Billion INR | 11.94% |
| 2007 | 19.69 Billion INR | 88.77% |
| 2006 | 10.43 Billion INR | -0.17% |
| 2005 | 10.45 Billion INR | 20.51% |
| 2004 | 8.67 Billion INR | 26.35% |
| 2003 | 6.86 Billion INR | 46.6% |
| 2002 | 4.68 Billion INR | 25.4% |
| 2001 | 3.73 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 26.48 Billion INR | 4.71% |
| 2024 Q3 | 25.29 Billion INR | 10.55% |
| 2024 Q1 | 21.9 Billion INR | -29.93% |
| 2024 Q2 | 22.88 Billion INR | 4.46% |
| 2024 FY | 98.29 Billion INR | -16.42% |
| 2023 Q3 | 23.6 Billion INR | 12.36% |
| 2023 Q4 | 31.26 Billion INR | 32.46% |
| 2023 FY | 117.61 Billion INR | 53.14% |
| 2023 Q2 | 21 Billion INR | 52.05% |
| 2023 Q1 | 13.81 Billion INR | -29.91% |
| 2022 Q3 | 19.35 Billion INR | -2.26% |
| 2022 Q4 | 19.7 Billion INR | 1.83% |
| 2022 Q2 | 19.8 Billion INR | 3.56% |
| 2022 Q1 | 19.12 Billion INR | 7.51% |
| 2022 FY | 76.8 Billion INR | 9.53% |
| 2021 Q1 | 16.64 Billion INR | 2.77% |
| 2021 FY | 70.11 Billion INR | 14.48% |
| 2021 Q2 | 17.31 Billion INR | 4.02% |
| 2021 Q3 | 18.36 Billion INR | 6.06% |
| 2021 Q4 | 17.78 Billion INR | -3.16% |
| 2020 Q1 | 11.92 Billion INR | -24.12% |
| 2020 FY | 61.24 Billion INR | -2.07% |
| 2020 Q4 | 16.19 Billion INR | -1.17% |
| 2020 Q3 | 16.39 Billion INR | -19.33% |
| 2020 Q2 | 20.31 Billion INR | 70.45% |
| 2019 Q2 | 16.32 Billion INR | 1.84% |
| 2019 Q1 | 16.02 Billion INR | -1.35% |
| 2019 FY | 62.54 Billion INR | -2.87% |
| 2019 Q3 | 15.02 Billion INR | -7.96% |
| 2019 Q4 | 15.7 Billion INR | 4.56% |
| 2018 Q2 | 15.09 Billion INR | -9.26% |
| 2018 FY | 64.38 Billion INR | -0.73% |
| 2018 Q4 | 16.24 Billion INR | -0.94% |
| 2018 Q3 | 16.4 Billion INR | 8.63% |
| 2018 Q1 | 16.64 Billion INR | 10.59% |
| 2017 FY | 64.85 Billion INR | 3.5% |
| 2017 Q3 | 16.12 Billion INR | -3.48% |
| 2017 Q2 | 16.7 Billion INR | -1.63% |
| 2017 Q1 | 16.98 Billion INR | 4.83% |
| 2017 Q4 | 15.04 Billion INR | -6.7% |
| 2016 Q2 | 15.21 Billion INR | 0.04% |
| 2016 Q3 | 16.01 Billion INR | 5.23% |
| 2016 FY | 62.66 Billion INR | 6.0% |
| 2016 Q1 | 15.2 Billion INR | 0.72% |
| 2016 Q4 | 16.2 Billion INR | 1.21% |
| 2015 FY | 59.11 Billion INR | 18.78% |
| 2015 Q2 | 14.52 Billion INR | 1.34% |
| 2015 Q1 | 14.32 Billion INR | 1.87% |
| 2015 Q4 | 15.1 Billion INR | -0.16% |
| 2015 Q3 | 15.12 Billion INR | 4.16% |
| 2014 FY | 49.76 Billion INR | 28.34% |
| 2014 Q4 | 14.06 Billion INR | 5.96% |
| 2014 Q3 | 13.27 Billion INR | 9.64% |
| 2014 Q2 | 12.1 Billion INR | 11.33% |
| 2014 Q1 | 10.87 Billion INR | 15.49% |
| 2013 Q4 | 9.41 Billion INR | -9.07% |
| 2013 Q1 | 9.62 Billion INR | 9.82% |
| 2013 Q2 | 9.37 Billion INR | -2.55% |
| 2013 FY | 38.77 Billion INR | 14.01% |
| 2013 Q3 | 10.35 Billion INR | 10.46% |
| 2012 Q1 | 7.76 Billion INR | 9.29% |
| 2012 Q3 | 9.02 Billion INR | 6.71% |
| 2012 FY | 34.01 Billion INR | 23.08% |
| 2012 Q4 | 8.76 Billion INR | -2.97% |
| 2012 Q2 | 8.46 Billion INR | 8.94% |
| 2011 Q2 | 6.75 Billion INR | 7.47% |
| 2011 FY | 27.63 Billion INR | 7.41% |
| 2011 Q4 | 7.1 Billion INR | -5.01% |
| 2011 Q3 | 7.48 Billion INR | 10.68% |
| 2011 Q1 | 6.28 Billion INR | -3.65% |
| 2010 Q1 | 6.91 Billion INR | 11.21% |
| 2010 Q2 | 6.17 Billion INR | -10.66% |
| 2010 Q3 | 6.15 Billion INR | -0.37% |
| 2010 Q4 | 6.52 Billion INR | 6.1% |
| 2010 FY | 25.72 Billion INR | 1.65% |
| 2009 Q3 | 6.51 Billion INR | 5.18% |
| 2009 FY | 25.31 Billion INR | 14.79% |
| 2009 Q4 | 6.21 Billion INR | -4.66% |
| 2009 Q2 | 6.19 Billion INR | 3.91% |
| 2009 Q1 | 5.96 Billion INR | 3.71% |
| 2008 Q3 | 7.31 Billion INR | 63.2% |
| 2008 FY | 22.05 Billion INR | 11.94% |
| 2008 Q1 | 4.01 Billion INR | -36.71% |
| 2008 Q2 | 4.48 Billion INR | 11.7% |
| 2008 Q4 | 5.75 Billion INR | -21.34% |
| 2007 Q1 | 4.27 Billion INR | 34.34% |
| 2007 Q3 | 4.65 Billion INR | 5.71% |
| 2007 Q2 | 4.39 Billion INR | 2.82% |
| 2007 FY | 19.69 Billion INR | 88.77% |
| 2007 Q4 | 6.33 Billion INR | 36.26% |
| 2006 Q2 | 2.27 Billion INR | -13.61% |
| 2006 Q1 | 2.63 Billion INR | -23.03% |
| 2006 FY | 10.43 Billion INR | -0.17% |
| 2006 Q4 | 3.18 Billion INR | 40.48% |
| 2006 Q3 | 2.26 Billion INR | -0.29% |
| 2005 Q1 | 2.58 Billion INR | -8.04% |
| 2005 Q4 | 3.41 Billion INR | 45.14% |
| 2005 Q3 | 2.35 Billion INR | -5.44% |
| 2005 FY | 10.45 Billion INR | 20.51% |
| 2005 Q2 | 2.49 Billion INR | -3.45% |
| 2004 Q1 | 1.81 Billion INR | -14.68% |
| 2004 FY | 8.67 Billion INR | 26.35% |
| 2004 Q3 | 2.09 Billion INR | 6.86% |
| 2004 Q4 | 2.8 Billion INR | 33.7% |
| 2004 Q2 | 1.96 Billion INR | 8.16% |
| 2003 Q2 | 1.71 Billion INR | 34.01% |
| 2003 FY | 6.86 Billion INR | 46.6% |
| 2003 Q1 | 1.28 Billion INR | -10.47% |
| 2003 Q3 | 1.74 Billion INR | 1.6% |
| 2003 Q4 | 2.12 Billion INR | 21.99% |
| 2002 Q1 | 911.78 Million INR | 0.0% |
| 2002 Q2 | 1.07 Billion INR | 17.9% |
| 2002 FY | 4.68 Billion INR | 25.4% |
| 2002 Q4 | 1.43 Billion INR | 12.99% |
| 2002 Q3 | 1.26 Billion INR | 17.87% |
| 2001 FY | 3.73 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 616.19 Million USD | -15459.786% |
| Bausch Health Companies Inc. | 5.23 Billion USD | -1731.48% |
| Catalent, Inc. | 1.7 Billion USD | -5533.255% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -9083.716% |
| Elanco Animal Health Incorporated | 1.61 Billion USD | -5847.767% |
| Perrigo Company plc | 1.52 Billion USD | -6172.686% |
| Teva Pharmaceutical Industries Limited | 4.45 Billion USD | -2054.078% |
| Zoetis Inc. | 2.76 Billion USD | -3367.559% |